New York-based Tauriga Sciences, Inc. (OTC:TAUG) has announced its plans to develop a Cannabigerol (“CBG”) Infused product to complement its existing Cannabidiol (“CBD”) Isolate Infused product line(s): Tauri-Gum™ and Tauri-Gummies. The Company may, alternatively, decide to acquire a CBG Infused product or product line – should such opportunity prove synergistic with existing business activities and infrastructure.
CBG is a non-psychoactive cannabinoid that plays an important role in the biochemistry of the cannabis plant. CBG acts as a chemical precursor to other cannabinoids such as THC and CBD. This conversion typically takes place six to weeks in the flowering cycle.
Said CEO Scott Shaw, “Over the past 18 months, the Company has established a considerable Research and Development infrastructure and capacity. With respect to the industry landscape and overall retail marketplace, the Company believes that the timing is prudent to develop or acquire a CBG Infused product offering as a diversification to Tauriga’s existing product lines.
Volume in the stock was taking some time to come around, registered early Thursday afternoon at a mere 11,000 shares. But the price is growing like, well, a weed, taking on 11.25% to 3.025 cents.
